Shafique Virani - 15 Aug 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief Business Officer
Signature: /s/ Jonathan Golightly, attorney-in-fact
Issuer symbol: RXRX
Transactions as of: 15 Aug 2022
Net transactions value: -$330,888
Form type: 4
Filing time: 17 Aug 2022, 18:35:33 UTC
Previous filing: 18 May 2022
Next filing: 16 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Tax liability	$7,944	-613	-0.59%	$12.96	103,773	15 Aug 2022	Direct	F1
transaction	RXRX	Class A Common Stock	Options Exercise	$55,500	+25,000	+24%	$2.22^*	128,773	16 Aug 2022	Direct	F2
transaction	RXRX	Class A Common Stock	Sale	$378,444	-30,000	-23%	$12.61	98,773	16 Aug 2022	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Options Exercise	$0	-25,000	-3.6%	$0.000000	661,955	16 Aug 2022	Class A Common Stock	25,000	$2.22	Direct	F2, F4
holding	RXRX	Stock Option (Right to Buy)						80,450	15 Aug 2022	Class A Common Stock	0	$11.40	Direct	F5
holding	RXRX	Stock Option (Right to Buy)						5,436	15 Aug 2022	Class A Common Stock	0	$11.40	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2	Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person
F3	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.06 to $12.96 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F4	One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
F5	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.